{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T11:22:43Z","timestamp":1768216963556,"version":"3.49.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Objective<\/jats:title>\n The effects of prophylactic administration of preclinical palonosetron hydrochloride (PH) and dexamethasone (DXMS) on nausea and vomiting (N\/V) induced by transcatheter arterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) were evaluated. The goal was to furnish evidence that could guide clinical nursing practices.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n A retrospective analysis was conducted on 112 patients with HCC between July and December 2022. They were categorized into two groups: those administered PH only (the PH group) and those administered a combination of PH and DXMS (the PH\u202f+\u202fDXMS group). Statistical tests including\n \u03c7<\/jats:italic>\n 2<\/jats:sup>\n , Fisher\u2019s exact test, paired\n t<\/jats:italic>\n -test, and logistic regression were employed to compare the occurrence of N\/V and identify associated factors.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n After TACE was administered, there was a significant increase in the occurrence of nausea (\n p<\/jats:italic>\n \u202f&lt;\u202f0.001) and vomiting (\n p<\/jats:italic>\n \u202f&lt;\u202f0.003) among patients in the PH group. Compared with the PH group, the frequency of nausea after TACE among patients in the PH\u202f+\u202fDXMS group was significantly reduced (67.2% vs. 37.8%, respectively;\n p<\/jats:italic>\n \u202f=\u202f0.004), and the frequency of vomiting was slightly reduced (26.9% vs. 8.9%, respectively;\n p<\/jats:italic>\n \u202f=\u202f0.060). Univariate analysis revealed that the prophylactic use of PH\u202f+\u202fDXMS prior to interventional treatment significantly reduced the days of hospitalization in patients with HCC experiencing intervention-induced nausea (\n p<\/jats:italic>\n \u202f=\u202f0.031). Logistic regression analysis revealed that the level of alanine aminotransferase (ALT) before TACE (OR\u202f=\u202f5.833, 95% CI: 1.252\u201327.170,\n p<\/jats:italic>\n \u202f=\u202f0.025) was an independent factor associated with the incidence of nausea.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Prophylactic administration of a combination of PH and DXMS reduced the frequency of N\/V as well as the length of hospital stay in patients with HCC. Moreover, the level of ALT before TACE was identified as a predictive factor for the incidence of nausea. Further research endeavors should explore patient-specific characteristics to optimize management strategies.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2025.1643731","type":"journal-article","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:12:13Z","timestamp":1768205533000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prophylactic use of a combination of palonosetron hydrochloride and dexamethasone to prevent transcatheter arterial chemoembolization-induced nausea and vomiting among patients with hepatocellular carcinoma"],"prefix":"10.3389","volume":"12","author":[{"given":"Wei-Mei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei-Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang-Fan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,12]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s42003-023-05664-7","article-title":"Suppressing MTERF3 inhibits proliferation of human hepatocellular carcinoma via ROS-mediated p38 MAPK activation","volume":"7","author":"Zheng","year":"2024","journal-title":"Commun Biol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3322\/caac.21338","article-title":"Cancer statistics in China, 2015","volume":"66","author":"Chen","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S0140-6736(19)30427-1","article-title":"Mortality, morbidity, and risk factors in China and its provinces, 1990\u20132017: a systematic analysis for the global burden of disease study 2017","volume":"394","author":"Zhou","year":"2019","journal-title":"Lancet"},{"key":"ref6","first-page":"629","article-title":"Comparison of the effects of postoperative prophylactic transcatheter arterial chemoembolization (TACE) and transhepatic arterial infusion (TAI) after hepatectomy for primary liver cancer","volume":"23","author":"Chen","year":"2018","journal-title":"J BUON"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v15.i12.1258","article-title":"Multifunctional roles of inflammation and its causative factors in primary liver cancer: a literature review","volume":"15","author":"Chen","year":"2023","journal-title":"World J Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","article-title":"Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial","volume":"69","author":"Kudo","year":"2020","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"100278","DOI":"10.1016\/j.ctarc.2020.100278","article-title":"Chemotherapy-induced nausea and vomiting: pathogenesis, recommendations, and new trends","volume":"26","author":"Gupta","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1515725","article-title":"Olanzapine for the prevention of chemotherapy-induced nausea and vomiting","volume":"375","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/hep.29403","article-title":"A randomized placebo-controlled trial of prophylactic dexamethasone for transcatheter arterial chemoembolization","volume":"67","author":"Ogasawara","year":"2018","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40265-013-0019-1","article-title":"Management of chemotherapy-induced nausea and vomiting: focus on newer agents and new uses for older agents","volume":"73","author":"Navari","year":"2013","journal-title":"Drugs"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1517\/14656566.2013.771166","article-title":"An update on palonosetron hydrochloride for the treatment of radio\/chemotherapy-induced nausea and vomiting","volume":"14","author":"Fabi","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"v232","DOI":"10.1093\/annonc\/mdq194","article-title":"Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference","volume":"21","author":"Roila","year":"2010","journal-title":"Ann Oncol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology clinical practice guideline update","volume":"29","author":"Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1113\/jphysiol.1953.sp004851","article-title":"Tryptamine receptors","volume":"119","author":"Gaddum","year":"1953","journal-title":"J Physiol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1476-5381.1957.tb00142.x","article-title":"Two kinds of tryptamine receptor","volume":"12","author":"Gaddum","year":"1957","journal-title":"Br J Pharmacol Chemother"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/j.1476-5381.1986.tb10228.x","article-title":"Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism","volume":"88","author":"Miner","year":"1986","journal-title":"Br J Pharmacol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.21873\/anticanres.11537","article-title":"Efficacy of single-dose first-generation 5-HT(3) receptor antagonist and dexamethasone for preventing nausea and vomiting induced by low-dose carboplatin-based chemotherapy","volume":"37","author":"Kaito","year":"2017","journal-title":"Anticancer Res"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.2146\/ajhp060355","article-title":"Physical and chemical stability of palonosetron hydrochloride with five opiate agonists during simulated Y-site administration","volume":"64","author":"Trissel","year":"2007","journal-title":"Am J Health Syst Pharm"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.2146\/ajhp070293","article-title":"Physical and chemical stability of palonosetron hydrochloride with five common parenteral drugs during simulated Y-site administration","volume":"65","author":"Kupie","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.arcmed.2008.04.007","article-title":"Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children","volume":"39","author":"Sepulveda-Vildosola","year":"2008","journal-title":"Arch Med Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s12630-015-0457-1","article-title":"Efficacy of palonosetron for preventing postoperative nausea and vomiting: a systematic review and meta-analysis","volume":"62","author":"Xiong","year":"2015","journal-title":"Can J Anaesth"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.2174\/0118744710261186231026062257","article-title":"Analysis of the efficacy and safety of palonosetron hydrochloride in preventing nausea and vomiting after TACE: a retrospective analysis","volume":"17","author":"Lu","year":"2024","journal-title":"Curr Radiopharm"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"387","DOI":"10.4137\/CMT.S4016","article-title":"Palonosetron hydrochloride in the prevention and treatment of postoperative nausea and vomiting","volume":"2","author":"Wallenborn","year":"2010","journal-title":"Clin Med Insights: Ther"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s00101-019-00672-x","article-title":"Perioperative dexamethasone","volume":"68","author":"Sinner","year":"2019","journal-title":"Anaesthesist"},{"key":"ref27","first-page":"58","article-title":"Dexamethasone to prevent postoperative nausea and vomiting: an updated meta-analysis of randomized controlled trials","volume-title":"Anesth Analg","author":"De Oliveira","year":"2013"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"e35433","DOI":"10.1097\/MD.0000000000035433","article-title":"Efficacy and safety analysis of dexamethasone + palonosetron in prevention of post-embolization syndrome after D-TACE: a retrospective study","volume":"102","author":"Lu","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.4103\/aer.AER_183_17","article-title":"Comparison of Palonosetron, dexamethasone, and Palonosetron plus dexamethasone as prophylactic antiemetic and antipruritic drug in patients receiving intrathecal morphine for lower segment cesarean section","volume":"12","author":"Swaro","year":"2018","journal-title":"Anesth Essays Res"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1080\/03007995.2021.1893677","article-title":"Efficacy of palonosetron-dexamethasone combination compared to palonosetron alone for prophylaxis against postoperative nausea and vomiting","volume":"37","author":"Jin","year":"2021","journal-title":"Curr Med Res Opin"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1213\/ANE.0000000000001617","article-title":"Combination of 5-HT3 antagonist and dexamethasone is superior to 5-HT3 antagonist alone for PONV prophylaxis after laparoscopic surgeries: a meta-analysis","volume":"123","author":"Som","year":"2016","journal-title":"Anesth Analg"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1007\/s00520-019-05178-1","article-title":"Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin","volume":"28","author":"Sakamoto","year":"2020","journal-title":"Support Care Cancer"},{"key":"ref33","first-page":"637","article-title":"Practical management of chemotherapy-induced nausea and vomiting","volume":"19","author":"Wiser","year":"2005","journal-title":"Oncology"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"E340","DOI":"10.1188\/12.ONF.E340-E345","article-title":"Malnutrition and chemotherapy-induced nausea and vomiting: implications for practice","volume":"39","author":"Davidson","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4103\/2311-8571.351510","article-title":"Systematic review and meta-analysis of acupuncture for pain caused by liver cancer","volume":"8","author":"Zhang","year":"2022","journal-title":"World J Tradit Chin Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1097\/00000441-195903000-00006","article-title":"Transaminases in serum and liver correlated with liver cell necrosis in needle aspiration biopsies","volume":"237","author":"Zelman","year":"1959","journal-title":"Am J Med Sci"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"451","DOI":"10.3390\/life14040451","article-title":"Endovascular drug delivery","volume":"14","author":"Lungu","year":"2024","journal-title":"Life (Basel)"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/cmr.s6460","article-title":"Palonosetron for the prevention of chemotherapy-induced nausea and vomiting: approval and efficacy","volume":"1","author":"Navari","year":"2009","journal-title":"Cancer Manag Res"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1002\/ijc.20507","article-title":"Prospective study on the risk of hepatocellular carcinoma among hepatitis C virus-positive blood donors focusing on demographic factors, alanine aminotransferase level at donation and interaction with hepatitis B virus","volume":"112","author":"Tanaka","year":"2004","journal-title":"Int J Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/ijc.21796","article-title":"Alanine aminotransferase level as a predictor of hepatitis C virus-associated hepatocellular carcinoma incidence in a community-based population in Japan","volume":"119","author":"Suruki","year":"2006","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643731\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T08:12:15Z","timestamp":1768205535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1643731\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":40,"alternative-id":["10.3389\/fmed.2025.1643731"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1643731","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,12]]},"article-number":"1643731"}}